JAMA Network Open study finds kickback penalties dwarfed by profits: $10.25 billion in penalties versus U.S. revenue of $458.6 billion on drug sales.
Pharmaceutical companies that were penalized for kickbacks paid only 2.2% of their U.S. revenue generated by selling drugs that were the focus of the alleged violations during the past quarter century, according to a new analysis.
Between 2000 and 20… [314 chars]
Source: STAT | Published: 2026-03-24T17:36:10Z
Credit: STAT
